Tactile Systems Technology (NASDAQ:TCMD) and Prourocare Medical (OTCMKTS:PUMD) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, risk, earnings and profitability.
Risk & Volatility
Tactile Systems Technology has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500. Comparatively, Prourocare Medical has a beta of 7.28, meaning that its share price is 628% more volatile than the S&P 500.
This is a summary of current ratings and recommmendations for Tactile Systems Technology and Prourocare Medical, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Tactile Systems Technology||0||2||3||0||2.60|
Tactile Systems Technology presently has a consensus target price of $78.50, indicating a potential upside of 41.47%. Given Tactile Systems Technology’s higher possible upside, equities research analysts clearly believe Tactile Systems Technology is more favorable than Prourocare Medical.
Earnings and Valuation
This table compares Tactile Systems Technology and Prourocare Medical’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Tactile Systems Technology||$143.75 million||7.27||$6.62 million||$0.34||163.21|
Tactile Systems Technology has higher revenue and earnings than Prourocare Medical.
Institutional & Insider Ownership
96.9% of Tactile Systems Technology shares are owned by institutional investors. 6.5% of Tactile Systems Technology shares are owned by insiders. Comparatively, 29.3% of Prourocare Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This table compares Tactile Systems Technology and Prourocare Medical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Tactile Systems Technology||5.27%||8.17%||6.76%|
Tactile Systems Technology beats Prourocare Medical on 7 of the 9 factors compared between the two stocks.
About Tactile Systems Technology
Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices for the treatment of chronic diseases in the United States. The company offers Flexitouch system, an at-home solution for lymphedema patients; and ACTitouch system, a home-based solution for chronic venous insufficiency patients. It also provides Entré System, a portable pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers; and Airwear Gradient Compression Wrap management of venous insufficiency, venous hypertension, venous ulcerations and lymphedema under the trade name Aero-Wrap. The company was founded in 1995 and is headquartered in Minneapolis, Minnesota.
About Prourocare Medical
ProUroCare Medical Inc. engages in developing products for the detection and characterization of male urological prostate disease. It offers the ProUroScan System, a prostate imaging system that aids the physician in documenting abnormalities in the prostate that have been previously detected by a digital rectal exam. The company has licensing, development, and commercialization agreements with Artann Laboratories Inc. for its ProUroScan System. ProUroCare Medical Inc. was founded in 1999 and is based in Eden Prairie, Minnesota.
Receive News & Ratings for Tactile Systems Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tactile Systems Technology and related companies with MarketBeat.com's FREE daily email newsletter.